ROIV|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'25 | $-0.45 | - | - |
| Q1'25 | $-0.16 | $-0.22 | -33.6% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'25 | $3M | - | - |
| Q1'25 | - | $8M | - |
Market Data
ROIV Stock Snapshot
ROIV is currently trading at $36.47, giving Roivant Sciences Ltd. a market cap of 26.25B. Today's range spans $35.68–$36.78, with shares opening at $35.86 and moving up $0.68 (1.9%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 47/100.
Over the past year ROIV has traded between $10.90 and $37.00 - the current price is +234.6% off the 52-week low and -1.4% from the high.
The bullish case for ROIV is built on complementary signals: 86/100 technical score, BUY designation, and neutral sentiment at 47/100. At $36.47 (near 52-week highs within $10.90–$37.00), the stock is at a capitalization - 26.25B - where active managers can build meaningful positions without moving the market. That combination of signal quality and position-buildability makes this one of the more actionable large-cap setups in Healthcare.
The combination of a BUY signal (86/100) and neutral news sentiment (47/100) puts ROIV on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 26.25B in Healthcare market cap without immediately moving the stock. At $36.47 (near 52-week highs in the $10.90–$37.00 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Investment Factors: Roivant Sciences (ROIV) (ROIV)
Biotech firms like Roivant are moderately sensitive to interest‑rate movements, as borrowing costs directly affect R&D budgets. In the current low‑rate environment, the company benefits from inexpensive capital, yet a tightening cycle could compress future cash‑flows. The stock sits near the 52‑week high of $37.00, having climbed 119.7 % from its low of $10.90, reflecting a bullish trajectory. Market cap of $26.25 billion places Roivant in the mid‑cap biotech segment, providing a balance between growth potential and liquidity. Over the past year, the share has returned 204.6 %, outpacing many peers, but the last month’s 3.7 % decline signals heightened volatility. These macro dynamics underscore that the stock’s performance is driven more by broader healthcare demand cycles than by isolated company news.
Platform Advantage
Roivant’s lipid nanoparticle and ligand conjugate platforms accelerate antibody delivery, reducing time to clinic and differentiating it from traditional biologics.
The modular platform enables rapid iteration across multiple disease areas, creating cross‑product synergies and lowering development costs.
Strategic partnerships, such as the pending Moderna settlement, provide capital and technology infusion that reinforce platform scalability.
Pipeline Breadth
The company’s pipeline spans autoimmune, rare disease, and pulmonary hypertension, covering high‑need therapeutic spaces with limited competition.
Candidates like IMVT‑1402 for Graves’ disease and mosliciguat for pulmonary hypertension qualify for orphan‑drug status, potentially accelerating regulatory review and premium pricing.
Early‑stage clinical data suggest favorable safety profiles, positioning the company for a steady stream of regulatory milestones.
Financial Health
With a market cap of $26.25 billion, Roivant remains a mid‑cap biotech, balancing growth potential with manageable capital intensity.
The anticipated $2.25 billion settlement from Moderna could double cash reserves, providing a buffer for R&D and potential acquisitions.
Despite negative EPS, revenue guidance is rising 78 % YoY, indicating a trajectory toward commercial viability as pipeline candidates mature.
Macro Sensitivity
Biotech valuations are moderately sensitive to interest‑rate hikes, as higher borrowing costs can dampen R&D investment and delay drug development timelines.
Roivant’s diversified pipeline mitigates pure rate risk, yet a prolonged rate‑up cycle could compress future cash‑flow projections.
Current bullish sentiment (score 65, rising trend) suggests market optimism amid low rates, but caution remains for potential tightening.
Valuation Upside
At $36.34, the stock sits 35 % above its 52‑week low, offering a potential 10 % upside to the analyst high of $42 before the 2026 earnings call.
The consensus target implies roughly 7 % upside from the current price, while the 52‑week high of $37 indicates a 1 % premium, signaling limited upside if the cycle stalls.
Relative to peers, Roivant trades at a discount to the average PE of 53, reflecting valuation pressure amid pipeline uncertainty.
Risk Landscape
Regulatory approval remains the single biggest hurdle; failure of any key candidate could erode projected revenue growth and investor confidence.
Insider sell activity and a recent Argus downgrade to $37 signal short‑term bearish sentiment, potentially amplifying volatility.
Macroeconomic tightening could increase borrowing costs and reduce capital availability for early‑stage biotechs, tightening the operating window.
Positioning ROIV
Positioning ROIV should align with its cyclical biotech nature, where earnings releases often drive large price swings. A prudent entry point emerges when the share price approaches the 52‑week low of $10.90, as mean‑reversion dynamics are historically reliable in the sector. Conversely, consider trimming exposure if the stock trades near the analyst high target of $42, indicating limited upside before the 2026 earnings announcement. Monitor the Q1 2026 earnings call for updates on pipeline milestones and the timing of the Moderna settlement, both of which could materially shift the valuation profile. If the company delivers on its 78 % revenue growth guidance and demonstrates a narrowing EPS gap, a re‑investment could be warranted. Maintain a balanced allocation that reflects the beta of the biotech index, ensuring the portfolio remains diversified across the broader healthcare cycle.
What Moves ROIV Stock?
Roivant’s share price is most sensitive to the timing of clinical milestones and the cash boost from the Moderna settlement, with R&D burn and valuation pressure acting as secondary forces. The stock has surged over 200% year‑to‑date, largely driven by pipeline announcements and the 52‑week high of $37. Rising sentiment, currently at 65, reflects growing confidence in the company’s platform strategy. Investors should watch for upcoming FDA filings and the settlement disbursement as key catalysts.
Pipeline Milestones
A single positive data point can lift the share price by 10‑15% in a short window, a pattern Roivant has repeated with IMVT‑1402 and brepocitinib. The 3‑month return of 28.5% reflects a series of approvals and partnership announcements that have kept momentum alive. Investors look for FDA filing dates, peer‑reviewed publications, and regulatory agency comments as early signals. The market quickly incorporates these developments into the forward multiple, often re‑pricing the company before the earnings call. Thus, pipeline news is the most volatile and influential driver for ROIV.
In 2025 Q1, revenue rose to $8M, a 20% jump from the prior quarter, driven by early sales of batoclimab in a pilot program. Despite the revenue lift, EPS remained negative, underscoring the cost intensity of early‑stage biopharma. Analysts have noted that each successful phase can unlock additional funding and broaden the commercial horizon. The pattern of incremental revenue growth aligns with the company's strategy of platform‑driven diversification. This track record reinforces the importance of upcoming data releases.
Roivant’s platform approach—lipid nanoparticles and ligand conjugates—allows rapid iteration across multiple indications. By leveraging a shared technology backbone, the company can reduce development time and cost per candidate. This modularity translates into a higher probability of achieving regulatory milestones, which in turn drives investor enthusiasm. The platform also attracts partnership deals, such as the recent collaboration with Moderna, adding credibility and financial support. Therefore, the pipeline's structural design is a core reason why each milestone has outsized price impact.
Moderna Settlement
The settlement announcement lifted the stock to a 52‑week high of $37, reflecting investor confidence in a sudden cash influx. If the payment is disbursed ahead of schedule, the company’s liquidity could support accelerated clinical development and reduce reliance on external financing. The market has priced in a potential upside of 5‑10% in the next few weeks, assuming the cash improves the balance sheet. Conversely, any delay or reduction would likely trigger a retracement. Thus, settlement timing is a key short‑term catalyst.
In 2023, a similar partnership with a major pharma partner injected $1.5 billion, leading to a 12% share price increase over the following month. Roivant’s own experience shows that large cash inflows can offset negative earnings and bolster investor sentiment, as seen in the 2024 earnings call where the company highlighted a $1.8 billion infusion. Analysts have tracked the settlement’s impact on the company’s debt‑to‑equity ratio, noting a projected decline to below 0.5 if fully realized. The historical pattern indicates that such deals often serve as a catalyst for both valuation and pipeline funding.
The settlement funds will be earmarked for R&D spend, potentially accelerating the development of IMVT‑1402 and brepocitinib. With additional capital, Roivant can afford larger Phase 3 trials, increasing the probability of regulatory approval. Moreover, the cash cushion allows the company to negotiate favorable licensing terms with smaller biotech partners, expanding its platform reach. This financial flexibility translates into higher expected future cash flows, which the market values. Therefore, the settlement is a structural driver that can shift the company’s valuation trajectory.
R&D Burn & Valuation
Persistent negative EPS and high R&D burn have kept the stock trading near the lower end of its 52‑week range, with a 6‑month return of 32.1% reflecting cautious sentiment. The 52‑week low of $10.9 and high of $37 illustrate the volatility tied to earnings guidance. Analysts have noted that the market discounts future cash flows heavily when burn exceeds cash runway. The current price, at $36.34, sits 119.7% above the 52‑week low, signaling potential upside if burn slows. Thus, burn dynamics are a critical short‑term valuation lever.
In Q1 2025, Roivant reported a loss of $0.22 per share, missing the estimate of $0.16, while revenue grew modestly. The company’s guidance for Q2 2025 projects $2.34 m in revenue, a 78% jump, yet EPS remains negative, illustrating the lag between revenue and profitability. Analysts have noted that early‑stage biotechs often require 5‑7 years before turning profitable, and this timeline is reflected in the current valuation multiples. The guidance also indicates a potential 30% increase in R&D spend to support upcoming trials. This pattern of negative earnings amid revenue growth is typical for the sector and keeps the stock within a cautious range.
Roivant’s business model relies on heavy upfront investment to bring candidates through clinical phases, which is reflected in its burn rate. The company’s platform strategy is intended to amortize development costs across multiple products, but the upfront costs still weigh on earnings. Investors evaluate the burn relative to cash runway; a higher burn reduces the probability of sustaining operations without additional funding. This risk factor has kept the market discounting future cash flows, resulting in a current share price that is sensitive to any changes in burn or capital structure. Therefore, R&D burn remains a core valuation driver.
Key insight: The most decisive factor for ROIV remains the pace at which its platform‑driven pipeline reaches regulatory milestones, amplified by the cash infusion from the Moderna settlement. While the company’s high burn and negative earnings create valuation pressure, each successful data release or partnership can quickly lift the share price. Investors should focus on upcoming clinical milestones, settlement disbursement dates, and any shifts in R&D spending to gauge the company’s trajectory.
Key Metrics for ROIV
Roivant Sciences operates in a high‑cycle, rate‑sensitive biotech environment where the timing of regulatory milestones and revenue guidance can swing valuation more than day‑to‑day market noise. In this context, investors must focus on the cadence of clinical progress, the trajectory of revenue expectations, and how earnings performance aligns with the company’s long‑term pipeline strategy. These metrics illuminate whether Roivant’s platform technology is delivering the promised speed to market and whether the market’s premium reflects realistic upside potential.
Clinical Milestone Cadence: A steady stream of on‑time clinical milestones signals that Roivant’s platform is functioning as intended and that future product launches are likely to materialize. When the company meets Phase 2 or Phase 3 endpoints on schedule, it often triggers a short‑term rally as investors reassess the probability of commercial success. Conversely, delays or setbacks can erode confidence and compress the valuation multiple. In the most recent quarter, Roivant announced a Phase 2 milestone for IMVT‑1402, reinforcing the pipeline’s momentum. Analysts will watch the Q2 2025 earnings call for updates on mosliciguat’s inhaled pulmonary hypertension trial, as a positive result could accelerate revenue upside. Sustained milestone delivery will likely keep the stock on an upward trajectory, while any lag could prompt a reassessment of the company’s growth narrative.
Guidance Growth Momentum: Roivant’s revenue guidance has surged, with Q1 2026 projected revenue at $4.23 million versus the $2.34 million estimate for Q2 2025—a 78% year‑over‑year lift. Such a jump signals that the company’s pipeline is moving closer to commercialization, which can justify a higher valuation multiple. However, the continued negative EPS forecast tempers enthusiasm, as profitability remains a distant horizon. Historically, a revenue guidance beat has lifted the stock, but only when accompanied by a narrowing earnings gap. Investors should track the guidance narrative in the upcoming earnings call, especially any revisions to the brepocitinib or batoclimab timelines. A sustained upward revision could reinforce the premium, while a flat or downward guidance would likely trigger a sell‑off.
EPS Consistency Under Pressure: In Q1 2025, Roivant reported an EPS of –$0.22 against an estimate of –$0.16, marking a miss that underscored the company’s ongoing investment‑heavy burn. The widening negative gap signals that R&D and clinical development costs are outpacing revenue growth. When the company narrows this gap or turns positive, it typically triggers a sharp rally, as the market reinterprets the path to profitability. The stock’s reaction to the Q1 miss was a decline, reflecting the consensus that earnings shortfalls are unsustainable at current valuation levels. Upcoming earnings will be pivotal; any improvement in the EPS trajectory could restore investor confidence. A continued negative EPS trend, however, will likely keep the stock languishing below its 52‑week low.
Consensus Gap Signal: Roivant’s current price of $36.34 sits between the analyst mean of $38.91 and the low of $34, indicating a modest undervaluation relative to the consensus. The spread of $8 between the high and low targets suggests significant uncertainty among analysts about the company’s upside potential. When the stock trades near the mean, it often reflects a balanced view of risk and reward; a move toward the high end could signal renewed optimism about pipeline milestones. Conversely, a slide toward the low end would reinforce concerns about regulatory hurdles and revenue timing. The market’s reaction to analyst revisions has been mixed—upgrades have spurred short‑term gains, while downgrades have led to sell pressure. Tracking future target adjustments will provide insight into whether the consensus is tightening or widening.
Return Trajectory Highlights: Over the past year, Roivant’s return has surged 204.6%, driven by a 28.5% gain in the last three months, despite a 3.7% dip in the most recent month. The positive long‑term trend suggests that the market is increasingly confident in the company’s pipeline, even as short‑term volatility persists. A 1‑month decline often precedes a rebound when new clinical data is released, as seen in the recent earnings call. The 3‑month rally indicates that investors are pricing in near‑term milestones, while the 1‑year surge reflects a broader reassessment of the company’s strategic positioning. If the 1‑month return rebounds, it could signal renewed momentum; a continued decline might prompt a reassessment of the valuation premium. Monitoring the next earnings cycle will be key to determining whether the upward trajectory persists.
Risk Factors
Roivant’s risk profile is dominated by the uncertainty of early‑stage development, the timing of a large cash settlement, and divergent analyst expectations. The company’s valuation is highly sensitive to clinical milestones and regulatory approvals, while its cash runway hinges on the settlement’s disbursement. Most risks are cyclical around the biotech development cycle rather than macroeconomic shocks, but a sudden regulatory setback could compress the multiple by 15‑20%. Monitoring clinical data releases, FDA docket updates, and settlement timelines will be key to gauging material risk.
- Pipeline Milestone Delay
A delay in advancing any of Roivant’s key candidates—such as IMVT-1402 or mosliciguat—could stall the company’s revenue trajectory. The company currently projects a 78% revenue increase for Q1 2026, but this hinges on reaching Phase 2 milestones by mid‑2025. If the IND or Phase 2 data are delayed beyond the first half of 2025, the guidance could be revised downward by 20‑30% and the cash runway shortened. Leading indicators include the quarterly clinical study reports and FDA meeting minutes, which are released in the second quarter. A lag in milestone achievement would likely surface in the Q2 2025 earnings call, where management would need to explain the delay and adjust expectations.
- Moderna Settlement Timing
The anticipated $2.25 billion cash infusion from the Moderna settlement hinges on the timely receipt of the payment. The company’s balance sheet would improve significantly, extending the runway to 2027 if the settlement is received by Q3 2025. A delay or partial payment would leave Roivant with a higher debt burden and could force a reduction in R&D spend by 15‑20%. Settlement status is tracked through the settlement agreement’s escrow schedule and quarterly financial statements. A late payment would become apparent in the Q3 2025 earnings release, prompting a reassessment of the company’s liquidity profile.
- Regulatory Approval Bottleneck
If the FDA extends review timelines for the company’s autoimmune indications, the launch window could shift beyond the current fiscal year. The company’s revenue guidance for 2026 is built on a 2026 launch of IMVT-1402, and a delay would push the first commercial cash flow to 2027, reducing the present value of expected earnings. Leading indicators include FDA docket updates and advisory committee meeting dates, which are publicly available. A prolonged review would be reflected in the Q1 2026 earnings call, where management would need to explain the delay and adjust the guidance. The impact could compress the valuation multiple by 10‑15% if the launch is postponed.
- Analyst Target Disagreement
The $8 spread between the highest and lowest analyst targets signals divergent views on Roivant’s upside potential. A narrow consensus would suggest confidence in the company’s pipeline, while a wide spread indicates uncertainty over regulatory approvals and milestone timing. The spread is currently 42.0 versus 34.0, implying a valuation range that could swing the share price by 20% if consensus shifts. Leading indicators are analyst conference calls and updated target revisions, which are released quarterly. A change in the spread would be evident in the next analyst meeting, potentially influencing market sentiment.
- Platform Technology Adoption
Roivant’s reliance on lipid nanoparticle and ligand conjugate platforms means that a failure to secure broader industry acceptance could limit its competitive edge. The company’s platform is central to its pipeline, and a lack of adoption would reduce the attractiveness of its candidates to partners and investors. Leading indicators include partnership announcements, licensing deals, and peer company platform performance, which are tracked in industry reports. A decline in platform adoption would likely surface in the Q2 2025 earnings call, where management would discuss partnership activity. The risk could compress the valuation multiple by 10% if the platform fails to gain traction.
Frequently Asked Questions About ROIV
Is Roivant Sciences (ROIV) stock a good investment in 2026?
Roivant Sciences (ROIV) operates in a highly cyclical biotech environment where pipeline progress and regulatory milestones drive valuation. In 2026 the company is expected to generate $4.23 million in revenue, a 78 % jump over the Q2 2025 estimate of $2.34 million, yet EPS remains negative. The 52‑week high of $37 and a current price of $36.34 place the stock near the upper end of its range, while a recent settlement with Moderna could inject up to $2.25 billion into the balance sheet. Analyst sentiment is rising, with a 65‑point score and 17 buy ratings out of 19 analysts. Given the high risk profile of early‑stage biotechs, the stock may appeal to investors willing to accept volatility for potential upside, but the negative earnings trajectory remains a cautionary signal.
What drives Roivant Sciences (ROIV) stock price?
The primary catalysts for Roivant Sciences (ROIV) stock are tied to its pipeline milestones, platform technology advancements, and partnership developments. Monoclonal antibody candidates such as IMVT‑1402 and batoclimab, along with the small‑molecule brepocitinib, are expected to reach pivotal clinical stages next year. The inhaled pulmonary hypertension agent mosliciguat is also on the launch trajectory, potentially adding new revenue streams. Macroeconomic factors like the overall health‑care R&D spend, which has grown at 5‑6 % annually, and the broader biotech cycle also influence investor sentiment. Finally, the settlement with Moderna, which could bring up to $2.25 billion, is a significant liquidity event that may temporarily lift the share price.
Does Roivant Sciences (ROIV) pay a dividend?
Roivant Sciences (ROIV) does not pay a dividend as the company is in a growth‑stage phase focused on funding research and development. There has been no announcement of a share‑buyback program, and the capital return policy remains centered on reinvesting proceeds into the pipeline. This approach is typical for clinical‑stage biotechs that prioritize scaling their therapeutic assets over shareholder payouts.
What are the risks of buying Roivant Sciences (ROIV)?
Buying Roivant Sciences (ROIV) carries several key risks that investors should weigh. First, the company’s pipeline is still in early clinical stages, so there is a high probability that key candidates will fail to meet regulatory milestones. Second, the firm’s earnings have consistently been negative, with the latest Q1 2025 EPS of –$0.21829 falling short of the –$0.16333 estimate, indicating ongoing burn. Third, insider sell activity and a recent Argus downgrade to $37 per share add short‑term bearish sentiment. Additionally, the timing and size of the Moderna settlement are uncertain, and broader macro downturns in the biotech sector could dampen valuation.
How has Roivant Sciences (ROIV) stock performed this year?
Roivant Sciences (ROIV) has posted a remarkable 1‑year return of 204.6 %, reflecting a strong rally since the start of 2025. Over the past 3 months the stock has gained 28.5 %, while a 1‑month decline of –3.7 % shows short‑term volatility. The 6‑month return of 32.1 % indicates sustained upside momentum, and the current price of $36.34 sits 119.7 % above the 52‑week low of $10.90. These gains outpace many peers in the biotech sector, suggesting that market participants are pricing in future pipeline progress. However, the high volatility underscores the inherent risk of investing in a clinical‑stage company.
What do analysts say about Roivant Sciences (ROIV)?
Analysts are largely bullish on Roivant Sciences (ROIV), with 17 buy ratings and only 2 hold recommendations out of 19 analysts. The consensus price target averages $38.91, with a high of $42 and a low of $34, indicating a 16 % upside from the current price. Sentiment scores have risen 15 points over the past 14 days, reflecting growing optimism about the company’s pipeline and upcoming earnings call. Despite the positive outlook, the firm’s negative earnings trajectory and reliance on a single settlement payment are noted as potential headwinds. Overall, the analyst consensus suggests that investors expect significant upside if the company can deliver on its clinical milestones.
What is the investment thesis for Roivant Sciences (ROIV)?
The investment thesis for Roivant Sciences (ROIV) centers on its unique platform technology that can accelerate drug development across multiple therapeutic areas. Monoclonal antibodies like IMVT‑1402 and batoclimab target autoimmune diseases, while brepocitinib offers a small‑molecule approach to dermatomyositis and uveitis. The inhaled agent mosliciguat is poised to address pulmonary hypertension, potentially opening a new revenue stream. Strategic partnerships, such as the potential $2.25 billion settlement with Moderna, could provide critical liquidity to fund these initiatives. If the company can navigate regulatory hurdles and achieve commercial launch, the upside could justify the current valuation, but the negative earnings and high burn rate remain significant risks.
How does Roivant Sciences (ROIV) compare to its peers in terms of valuation?
Compared to its peers, Roivant Sciences (ROIV) trades at a lower valuation, as it lacks a forward P/E due to ongoing losses. The peer average P/E of 53.0 places most biotech competitors at a higher multiple, reflecting their more mature earnings streams. Roivant’s current price of $36.34 is roughly 35.3 % below its 52‑week high, suggesting a potential discount relative to the sector. However, the company’s pipeline diversity and platform technology could justify a higher multiple once it demonstrates commercial viability. Investors looking for value may find Roivant attractive if the firm can close the earnings gap and deliver on its pipeline milestones.
What is Roivant Sciences (ROIV)'s competitive positioning in the biotech sector?
Roivant Sciences (ROIV) differentiates itself in the biotech arena through a proprietary platform that combines lipid nanoparticles and ligand conjugates to enhance drug delivery. Its pipeline spans autoimmune diseases, rare conditions, and pulmonary hypertension, giving it a broader therapeutic footprint than many peers focused on a single indication. Unlike AbbVie (ABBV) or AbbV, which rely heavily on established biologics, Roivant’s early‑stage assets offer higher upside potential but also higher risk. The company’s focus on platform scalability allows it to potentially launch multiple products from a single technology stack, a competitive advantage in the fast‑evolving biotech landscape. Nonetheless, the lack of a proven commercial product limits current revenue generation, keeping Roivant in a high‑growth, high‑risk category.
What are the primary price drivers for Roivant Sciences (ROIV) in the current cycle?
In the current biotech cycle, Roivant Sciences (ROIV) is influenced by several macro drivers that outweigh company‑specific news. Interest rate hikes have tightened capital markets, making it more expensive for biotechs to secure funding for late‑stage trials. Conversely, increasing global R&D spend in pharmaceuticals—projected to grow 5‑6 % annually—creates a favorable environment for pipeline development. Regulatory momentum, particularly the FDA’s accelerated approval pathways, can accelerate the path to market for candidates like mosliciguat. These broader economic forces shape investor sentiment and can amplify the impact of any clinical milestone or partnership announcement.
How has Roivant Sciences (ROIV) revenue trended over the past quarter?
Roivant Sciences (ROIV) reported $8.0 million in revenue for Q1 2025, a modest increase over the $7.57 million figure mentioned in the earnings summary. Guidance for Q2 2025 projects revenue of $2.34 million, while the Q1 2026 outlook estimates $4.23 million, representing a 78 % jump from the Q2 2025 estimate. The company’s revenue guidance trajectory suggests a gradual ramp‑up as more pipeline candidates reach later trial phases. However, the revenue numbers remain small relative to the company’s $26.25 billion market cap, underscoring the early‑stage nature of the business. Continued revenue growth will depend on successful clinical outcomes and potential licensing or partnership deals.
What was Roivant Sciences (ROIV)'s earnings performance in Q1 2025?
In Q1 2025 Roivant Sciences (ROIV) posted earnings per share of –$0.21829, missing the consensus estimate of –$0.16333. Revenue for the quarter was $8.0 million, with no comparable estimate provided for comparison. The negative earnings reflect ongoing R&D expenses and the lack of a commercial product pipeline. This pattern of earnings misses is consistent with the company’s clinical‑stage status and high burn rate. Investors will likely focus on whether the company can turn these numbers around in the next reporting period.
Learn More
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
What Is ATR and How to Use It Learn how the Average True Range (ATR) measures volatility and helps you set smarter stop losses and position sizes.
Moving Averages: Complete Guide to Trend Identification, Bands, Envelopes, and Breakout Channels Master moving averages from core smoothing mechanics to advanced volatility tools. Learn SMA vs EMA, crossover signals, whipsaws, envelopes, Bollinger/Keltner/STARC bands, Donchian breakouts, and how institutions confirm trends and filter false signals.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).